MAP2K7 and melanoma: Previous studies have shown that ErbB3 is a key factor in the development of adaptive resistance to BRAF and Mek inhibitors, albeit with different mechanisms, and that ErbB3 inhibition with monoclonal antibodies is able to potentiate the efficacy of target therapy in melanoma [8,15,19,20,21].